Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

<p>NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/arvinas-and-pfizer-announce-upcoming-vepdegestrant-arv-471-poster-presentation-at-esmo-congress-2023/">Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>